MabVax Therapeutics, Incdan2023-12-14T23:34:25-05:00 Project Description Follow-On Offering Common and Preferred Stock $4,100,000 Sole Book-Runner May 2017 Project Details Categories: Healthcare Related Projects
Stay In Touch